The mixed-lineage leukemia gene (MLL) is associated with more than 25 chromosomal translocations involving band 11q23 in diverse subtypes of human acute leukemia. Conditional expression of a 50 kDa amino terminal fragment spanning the AT hook motifs of MLL (MLL3AT) causes cell cycle arrest, upregulation of p21 Cip1 and p27 Kip1 and partial monocytic differentiation of the monoblastic U937 cell line, suggesting a major role for MLL3AT in MLL-AF9-induced myelomonocytic differentiation. In this study, we analyzed the subcellular localization of conditionally expressed MLL3AT in both U937 and HeLa cell lines. Immunofluorescence staining, confocal laser scanning microscopy and immunoelectron microscopy indicated that MLL3AT, like endogenous MLL, localized in the nucleoplasm in a punctate pattern of distribution, including regions attached to the nuclear envelope and the periphery of the nucleolus. We found that MLL3AT and endogenous MLL were present in interphase nuclear matrices and colocalized with topoisomerase II to mitotic chromosomal scaffolds. Nucleoplasm and nucleolar localization was observed even for MLL-AF9 and MLL-AF4 conditionally expressed chimeric proteins, suggesting a common target conferred by the amino terminus of MLL to many if not all the chimeric MLL proteins. The nuclear matrix/scaffold association suggests a role for the amino terminus of MLL in the modulation of chromatin structure, leading to epigenetic effects on the maintenance of gene expression.
Introduction
The mixed-lineage leukemia (MLL) gene on chromosome band 11q23 is a recurring target of reciprocal translocations in human acute leukemias. 1 Chimeric MLL genes are found in 7-10% of acute lymphoblastic leukemia (ALL), 2 5-6% of acute myeloblastic leukemia (AML), 3 and more than 80% of cases of topoisomerase II inhibitor-associated secondary AML. 4, 5 In all cases studied, the breakpoints within the MLL gene were localized in an 8.5 kb breakpoint cluster region positioned between exons 5 and 11. 6 The 17 plus fusion partner genes that have been cloned to date share little sequence homology, with each partner representing a major subtype of acute leukemia. The most common 11q23 rearrangement, t(4;11)(q23;q21), is found in approximately 4% of cases of childhood pro-B ALL overall, with a third of such cases occurring in infants. [7] [8] [9] [10] Tandem duplications of portions of MLL gene spanning exons 2-6 or 2-8 have been reported in AML patients with a normal karyotype, indicating that self-fusion and consequent MLL partial duplication is an additional genetic mechanism for leukemogenesis. 11 As a result of each 11q23 rearrangement the amino terminal segment of MLL is fused in frame with itself or with a carboxyl terminal portion coded by a partner gene. MLL -also called ALL-1, 12,13 HRX 14 and Htrx1 15 -is a large protein of 3968 amino acids and a predicted molecular mass of 431 kDa. It contains a central zinc-finger domain (PHD) homologous to those of the Drosophila protein Trithorax (Trx), [16] [17] [18] a domain with transactivation activity in vivo, 19, 20 and a carboxyl terminal SET domain homologous to regions of the Suppression of variegation 3-9 [Su(var) [3] [4] [5] [6] [7] [8] [9] , Enhancer of zeste [E(z)] and Trithorax Drosophila proteins. 21 Trx and E(z) are encoded by members of the trx and Polycomb groups (trx-G and Pc-G) of developmental regulatory genes, respectively. During the early stages of development in the fly, these genes play major roles in the maintenance of clustered homeotic (HOM-C) gene expression, which regulates formation of the axial body plan (reviewed in Refs. 22, 23) . Trx-G and Pc-G gene products positively or negatively affect transcription of their target genes respectively, and are thought to act at the level of higher-order chromatin structure. The multiple regions of homology between MLL and Trx provided the first hint that MLL is the mammalian counterpart of the Drosophila protein, a hypothesis supported by the pattern of segmentation defects in mice haploinsufficient for functional Mll genes, including demonstrable defects in Hox gene expression. 24 Furthermore, antagonistic roles of Mll and the Pc-G homologue Bmi1 protooncogene were recently demonstrated in determining segmental identity and regulation of Hox gene expression during mammalian development. [25] [26] [27] The PHD fingers, the transactivation and the SET domains are encoded by sequence 3′ to the breakpoint cluster region, and their loss in MLL fusion proteins may be important in leukemogenesis. In addition, MLL contains two amino terminal domains that are necessary for leukemic transformation. 28 The first consists of three AT-hooks motifs that are not present in Drosophila Trx, which are similar to those that mediate the binding of the high mobility group proteins HMGI-C and HMG-I(Y) to AT-rich tracks of double-stranded DNA via minor groove contacts. 29 The second motif is a 45 amino acid, cysteine-rich domain homologous to the zinc-binding domain of the DNA methyltransferases (MTs), 30 and to the protein-containing methyl-CpG binding domain (PCM1), a component of the mammalian methyl-CpG sequence-specific transcriptional repressor complex MeCP1. 31 The MT homologous region of MLL is part of a domain with transcriptional repressor activity in vivo. 19, 20 All known oncogenic MLL fusion proteins found in the acute leukemias contain the AT-hook and MT domains.
Recently, as a first step toward defining the role of motifs retained in MLL fusion proteins in MLL-mediated leukemogenesis, we used a conditional expression system to examine the effects of full-length MLL-AF9 -the product of the t(9;11)(p21;q23) translocation 32 -or truncated MLL proteins on cell cycle progression and monocytic differentiation of the U937 promonocytic cell line. We found that MLL-AF9 is a potent inducer of macrophage differentiation and cell death and that small amino terminal portions of MLL containing two (MLL2AT) or three (MLL3AT) AT-hook motifs are sufficient for G0/G1 cell cycle arrest, p21
Cip1 and p27 Kip1 upregulation, and for promotion of macrophage differentiation. 33 In the current study, immunofluorescence, confocal laser scanning and immunoelectron microscopic techniques were employed to study the nuclear distribution of ectopically expressed epitope-tagged MLL3AT protein and compare it to ectopic MLL-AF4 and endogenous MLL.
Materials and methods

Antibodies
The nucleotide sequence described by Domer et al 9 was used as a reference for designating nucleotide and amino acids positions within the MLL cDNA and protein. The cDNA encoding MLL amino acids 554-758 (M612 fragment) and 759-886 (M382 fragment) were subcloned in the pGEX-3X (Pharmacia Biotech, Piscataway, NJ, USA) and expressed in bacteria under conditions suggested by the manufacturer. The resultant glutathione S-transferase fusion proteins (GST-M612 and GST-M382) were purified by glutathione Sepharose 4B chromatography, and then used as antigens to raise rabbit ␣-MLL polyclonal antibodies (pAbs). Antisera were collected 4 weeks after the booster injection, and 10-15 days after further injections. Immunoglobulin (IgG) fractions of pAb M612 and pAb M382 were affinity purified by Sepharose CL4B-protein A chromatography (Pharmacia Biotech). The hamster ␣-MLL mAb 2F7 (kindly provided by Stanley Korsmeyer, Dana-Farber Cancer Institute, Boston, MA, USA) was prepared with MLL amino acids 1148-1258 as the immunogen. The affinity purified rabbit ␣-AF4 pAb C15 (kindly provided by Quanzhi Li and John H Kersey, University of Minnesota Cancer Center, Minneapolis, MN, USA) were raised against amino acids 1942-2242 of AF4. 34 
DNA constructions
The MLL3AT fragment was generated from an MLL-AF4 cDNA which contained a stop codon at amino acid 410 as a result of a nucleotide substitution that apparently arose during cloning. 9 A full-length MLL-AF4 cDNA was generated by in frame fusion of a 5′ BamHI MLL cDNA fragment (kindly provided by Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy) with the 3′ BamHI fragment of the MLL-AF4 cDNA. Both MLL3AT and MLL-AF4 cDNAs were modified by the addition of a double-stranded oligonucleotide encoding the amino terLeukemia minal FLAG epitope (MDYKDDDDK), beginning with an ATG codon in a Kozak consensus sequence. The pUHD/MLL-AF4 and pUHD/MLL3AT vectors were constructed by subcloning the FLAG-tagged cDNAs into the BstXI and XhoI cloning sites of pUHD10B/X, a modified version of pUHD10S expression vector. 33 
Cell culture and transfections
The HtTA-1 HeLa carcinoma cell line, 35 which constitutively expresses a tetracycline (tet)-responsive transactivator TetR-VP16 (tTA), was provided to us by Drs Manfred Gossen and Hermann Bujard (University of Heidelberg, Heidelberg, Germany). HtTA-1 cells were stably co-transfected by calcium phosphate/DNA precipitation of pUHD/MLL3AT with the hygromycin B-resistance plasmid pGEM-HYG at a 10:1 molar ratio, and selected by 3-4 weeks growth in Dulbecco's modified Eagle's medium supplemented with 10% FCS (DMEM-F), 0.5 mg/ml G418, 0.5 mg/ml Hyg B, and 1 g/ml tet. Single hygromycin-resistant clones showing inducible expression of MLL3AT were identified by Western analysis with an ␣-FLAG mAb. Clones were expanded and routinely maintained at subconfluence in DMEM-F, 0.4 mg/ml G418, 0.4 mg/ml Hyg B, 1 g/ml tet. Transient transfection of HtTA-1 cells was done by calcium phosphate/DNA precipitation of pUHD/MLL-AF4 plasmid in the presence of tetracycline. Transiently transfected cells were washed in PBS to remove tet, incubated for 24 h in DMEM-F and analyzed by immunofluorescence staining. The promonocytic leukemia cell line U937T (kindly provided by Gerard Grosveld, St Jude Children's Research Hospital, Memphis, TN, USA) was obtained by stable transfection of U937 cells with the pUHD-pTet/tTApuro vector. The vector encodes the tTA, whose expression is autoregulated by tet operator sequences in the promoter (pTet). U937T clones conditionally expressing MLL3AT 33 were routinely maintained in RPMI 1640 medium supplemented with 10% FCS (RPMI-F), 0.5 g/ml puromycin, 0.4 mg/ml Hyg B, 1 g/ml tet. The acute mixed lineage cell lines RS(4;11) 36 and ALL-PO(4;11) 37 and the Jurkat T cell line were maintained in RPMI-F.
Western analysis
HtTA-1 or U937T cells conditionally expressing MLL3AT were grown for 48 h in the presence or absence of tetracycline (1 g/ml). RS(4;11) and ALL-PO(4;11) cells were diluted at log phase density and grown for 24 h. Aliquots of 2 × 10 6 cells were washed twice with ice-cold PBS and sonicated at maximum intensity for 10 s. The cell lysate was incubated on ice and the protein concentration measured by Bradford assay (BioRad, Hercules, CA, USA). The samples (50 Ϭ 100 g) were solubilized in 2× sample buffer, boiled for 5 min and run on 5% or 10% SDS-PAGE and subsequently blotted on nitrocellulose membranes. Membranes were blocked for 16 h with 5% skim milk powder in PBS (5 × BLOTTO) at 4°C, incubated for 2 h with 1:200 dilution of affinity purified pAb M382 (or pAb M612), 1:100 dilution of mAb 2F7, 1:100 dilution of pAb C15, or 10 g/ml ␣FLAG mAb in 3× BLOTTO at room temperature, and washed three times in 1× PBS, 0.05% Tween 20 (TPBS), 10 min each. The filters were then incubated for 1 h with 1:4000 dilution of HRP-conjugated donkey ␣-rabbit 
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The proteins were then detected by chemiluminescence following SuperSignal ULTRA protocol (Pierce, Rockford, IL, USA).
Nuclear matrix preparation
Cell extractions were performed as described by He et al, 38 with several modifications. After growth for 48 hrs in media with or without 1 g/ml tet, HtTA-1 parental cells or conditionally expressing MLL3AT were collected, washed three times with 10 ml of PBS and then extracted in cytoskeleton (CSK) buffer (10 mM Pipes (pH 6.8), 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 1.2 mM PMSF, 5 g/ml aprotinin, 5 g/ml leupeptin, 1 g/ml pepstatin and 0.5% (v/v) Triton X-100) for 15 min on ice. The extracts were pelleted by centrifugation at 600 g for 5 min and resuspended in nucleoskeleton buffer (CSK buffer plus 100 g/ml DNase I, 20 U/ml HaeIII, with or without 50 g/ml RNase A). Lysates were incubated for 30 min at room temperature, chromatin was removed by adding ammonium sulfate to a final concentration of 0.25 M, and the preparations were centrifuged as above. Pellets were resuspended in CSK buffer and extracted by adding the equal volume of CSK buffer containing 4 M NaCl to a final concentration of 2 M NaCl. After 15 min of incubation on ice, the final nuclear matrix intermediate filament preparation was centrifuged at 600 g for 10 min, resuspended in CSK buffer and cytocentrifuged on microscope slides. The preparations were then fixed and processed for indirect immunofluorescence analysis.
Indirect immunofluorescence and immunoelectron microscopy
Parental or transfected HtTA-1 cells were extensively washed with PBS containing 2% FCS and 5 × 10 4 cells were grown for 24-48 h in DMEM-F at 37°C in 5% CO 2 on two-chamber slides (Nunc, Naperville, IL, USA). Exponentially growing U937T clones were repeatedly washed with PBS containing 2% FCS, diluted at cell density of 1 × 10 5 cells/ml and cultured in RPMI-F for 48 h. Cells were cytocentrifuged at 500 r.p.m. on microscope slides and air-dried for 20 min. Indirect immunofluorescence analysis was performed as described previously by Murti et al. 39 Cells were fixed with 3.7% paraformaldehyde for 20 min, washed three times with PBS and permeabilized in PBS plus 0.2% Triton-X100 for 10 min at room temperature. The slides were washed three times with PBS, preincubated with 5% skim milk, 1% normal horse serum in PBS for 30 min at room temperature, and then incubated with ␣-FLAG mAb M2 or M5 (10 g/ml), pAb M382 (1/50), mAb 2F7 (1/10) pAb C15 (1/40), or an ␣-topoisomerase II pAb (1/50) for 1 h at room temperature in a humified chamber. M382 preimmune serum at the same dilution was used as negative control. Cells were washed four times with PBS, and then incubated with FITC-conjugated goat ␣-mouse IgG (1/200), Texas red-conjugated goat ␣-rabbit IgG (1:100), Texas red-conjugated goat ␣-Armenian hamster IgG (1:200), or gold-conjugated goat ␣-mouse IgG (1/100) for 30 min at room temperature. The samples were examined in a Zeiss IM35 microscope (Zeiss, Thornwood, NY, USA) equipped with epifluorescence optics for rhodamine/Texas red and FITC or in a confocal laser scanning microscope (BioRad MRC 1000). Immunogold-electron microscopy was performed exactly as described by Murti et al. 40 
Results
Specificity of anti-MLL antibodies
We generated two rabbit polyclonal antibodies, M382 and M612, which recognize distinct epitopes on the amino terminus of MLL. A third anti-MLL hamster monoclonal antibody, 2F7, provided by Stanley Korsmeyer, was raised against an epitope proximal to the DNA methytransferase homology region (Figure 1a) . The specificity of all affinity purified anti-MLL antibodies was first evaluated by Western analysis of two different cell lines carrying the translocation t(4;11), RS(4;11) 36 and ALL-PO(4;11), 37 and the T cell line Jurkat (Figure 1b) . A side-by-side comparison of the anti-MLL antibodies pAb M382 and mAb 2F7 with the anti-AF4 polyclonal antibody C15, 34 provided by John H Kersey, showed that all three antibodies were able to recognize a protein band with a calculated molecular weight of 240 kDa in both RS(4;11) and ALL- Figure 1 (a) Structures of MLL, AF4, MLL-AF4 proteins and MLL3AT mutant. MLL-AF4 contains all regions upstream of the breakpoint cluster region (BCR) of MLL and all but the most amino terminal portion of AF4. 9, 10, 13 MLL3AT encodes the amino terminal 410 amino acids of MLL and includes three AT-hook motifs that share homology with minor-groove DNA-binding proteins. 29, 33 Both constructs contain an amino terminal FLAG epitope tag. SNL-1 and SNL-2, speckle nuclear localization domains 1 and 2;
53 trx, short regions of homology to Trithorax Drosophila protein; 53 MT, DNA methyltransferase homology region; 9,30,31 NLS, nuclear localization signal of AF4; 10 PHD, plant homeodomain zinc-fingers; [13] [14] [15] [16] [17] [18] SET, domain of homology to regions of Su(var)3-9, E(z), and Trx Drosophila proteins. 21 The relative positions of the peptides used to produce antibodies against MLL-AF4 are also shown. (b) Comparison of ␣-MLL pAb M382 and mAb 2F7 antibodies with ␣-AF4 polyclonal antibody C15. Lysates from t(4;11) and non-t(4;11) leukemia cell lines (100 g) were run on low percentage SDS-PAGE (5%), electrophoretically transferred to nitrocellulose membranes, and probed with affinity purified ␣-MLL pAb M382 and mAb 2F7 or ␣-AF4 pAb C15. Lane 1, Jurkat; lane 2, RS(4;11); lane 3, ALL-PO(4;11). PO(4;11) cell lines. None of these antibodies detected the 240 kDa protein in the Jurkat cell line, indicating that the protein is the MLL-AF4 fusion oncoprotein of predicted molecular mass. On the other hand, the Jurkat cell line shared with the two t(4;11)-carrying cell lines a higher band with a calculated molecular weight of 300 kDa, which is recognized by both anti-MLL pAb M382 and mAb 2F7 but not the anti-AF4 pAb C15 (Figure 1b, asterisk) . It is possible that this band represents the amino terminal portion of MLL resulting from proteolytic cleavage of the expected 431 kDa protein, as detected by Joh et al 41 for MLL COS cell transfectants, and by Kuzin et al 42 
34
MLL and MLL3AT display identical nuclear distribution
An MLL3AT mutant was generated that encoded for three AThook motifs in an amino terminal FLAG epitope-tagged protein of approximately 50 kDa (Figure 1a) . MLL3AT was subcloned into the pUHD-10S expression vector under control of a tetracycline (tet)-responsive promoter. This vector was stably transfected into two different recipient cell lines of the tetoff conditional expression system: the HeLa carcinoma clone HtTA-1, and the promonocytic leukemia clone U937T. 33 Western analysis employing an ␣-FLAG mAb was used to select HtTA-1 or U937T clones with tet-regulatable expression of MLL3AT, and three of each type were chosen for the subcellular localization study (Figure 2 ). Unlike the U937T
Figure 2
Western analysis of FLAG-tagged MLL3AT after conditional expression in HtTA-1 and U937T stably transfected cells. Total cell lysates (50 g) prepared from each clone grown for 48 h in the presence (+) or absence (−) of transcriptional repressor tetracycline were separated by SDS-PAGE, and transferred on to nitrocellulose membranes. Western analysis was performed using an ␣FLAG monoclonal antibody. In the absence of tetracycline all clones express a protein of 50 kDa, as predicted for MLL3AT. The band does not show up in parental HtTA-1 and U937T control cells.
Leukemia clones, HtTA-1 clones showed normal rates of proliferation after induction of cell cycle arrest (data not shown).
Immunofluorescence studies with the ␣-FLAG mAb and two different anti-MLL antibodies (pAb M382 and mAb 2F7) were performed to determine the relative subcellular location of ectopically expressed MLL3AT compared to the endogenous MLL. The ␣-MLL antibodies were expected to cross-react with the endogenous MLL but not with conditionally expressed MLL3AT, whereas the ␣-FLAG mAb was expected to label only the FLAG-tagged ectopic protein. HtTA-1 cells induced to express MLL3AT were labeled with both rabbit pAb M382 (Figure 3a) and mouse ␣-FLAG mAb (Figure 3b) . Binding of pAb M382 or the ␣-FLAG mAb was detected with secondary antibodies conjugated to Texas red and fluorescein, respectively. Most, but not all, of the HtTA-1 cells grown in the absence of tet expressed MLL3AT, as detected with ␣-FLAG mAb (Figure 3b) . The ␣-FLAG mAb detected MLL3AT in the nucleoplasm of conditionally expressing HtTA-1 cells (arrows). The protein showed a punctate distribution pattern (100 to 200 dots per nucleus); cytoplasmic staining was not observed. In the absence of tet, nucleoli were intensely labeled by the ␣-FLAG mAb, whereas in its presence (1 g/ml) there was no evidence of labeling (data not shown).
As expected, pAb M382 reacted with all HtTA-1 cells (Figure 3a) . Importantly, endogenous MLL stained by pAb M382 showed the same nucleolar (arrowhead) and nucleoplasmic distribution patterns observed for MLL3AT. The nucleoplasmic and nucleolar staining of pAb M382 appeared to be specific since it was not found when cells were stained with the corresponding preimmune rabbit serum (data not shown). Similar nucleolar and nucleoplasmic distribution patterns were observed when U937T cells conditionally expressing MLL3AT were co-stained with pAb M382 (Figure 3c ) and ␣-FLAG mAb (Figure 3d) .
To further confirm the pattern of distribution of the endogenous MLL protein, we performed an immunofluorescence study on HeLa parental cells (HtTA-1 clone) or HtTA-1 cells ectopically expressing MLL3AT using the hamster mAb 2F7 followed by Texas Red-conjugated secondary antibodies. As shown in Figure 3e the mAb 2F7 stained the nucleus in a punctate pattern, and also stained the nucleoli of a consistent fraction of HeLa cells. This antibody also stained the nucleoli of HtTA-1 cells ectopically expressing the MLL3AT protein, in a pattern perfectly overlapping that obtained with the ␣-FLAG mAb (Figure 3f-h) . Thus, MLL3AT and native MLL showed identical nuclear localization patterns.
MLL and MLL3AT associate with nuclear matrix and chromosomal scaffold
The interphase nucleus of eukaryotic cells contains a proteinaceous matrix thought to organize this compartment into structural and functional domains. The scaffolding of metaphase chromosomes is also believed to be derived from this matrix. [43] [44] [45] To test the possibility that MLL might be associated with the nuclear matrix and chromosomal scaffolds, we used immunofluorescence microscopy to evaluate the relative locations of MLL3AT and topoisomerase II, a major component of the proteinaceous scaffolds. [46] [47] [48] [49] HeLa cells expressing MLL3AT were labeled with ␣-FLAG mAb (fluorescein) and an ␣-topoisomerase II polyclonal antibody (Texas red), and then examined by fluorescence or confocal laser scanning microscopy. By immunofluorescence, the distribution of ␣-FLAG mAb (Figure 4a ) and ␣-topoisomerase II pAb (Figure 4b ) correlated well in cells in telophase or those undergoing cytokinesis. Examination of 0.7-m optical sections of the same preparation by confocal laser scanning (Figure 4c ) revealed strong colocalization of the ␣-FLAG and ␣-topoisomerase II in metaphase (M) and telophase (T) chromosomes (red + green = yellow). Interphase (I) cells and prophase (P) cells also showed some overlap of the two labels, but this result was far less striking than that observed for mitotic chromosomes. Thus, MLL3AT appears to colocalize with topoisomerase II, a known component of the chromosomal scaffolding.
Immunofluorescence microscopy of the interphase nuclear matrix and chromatin-depleted (telophase) chromosomes of HtTA-1 cells expressing MLL3AT revealed identical labeling patterns with either ␣-FLAG mAb (Figure 4d ) or ␣-MLL mAb 2F7 (Figure 4e ). There was no indication of nucleolar labeling by ␣-FLAG or ␣-MLL mAb 2F7 in any of the nucleoskeletal preparations, indicating the removal of the MLL proteins from this structure. Similar results were obtained with matrices prepared by a harsher procedure that removes RNA in addition to soluble proteins and DNA (data not shown). Taken together, these findings suggest an intimate association of MLL protein with the interphase nuclear matrix and mitotic chromosomal scaffolding, which is mediated by amino terminal sequences spanning the AT-hook motifs.
Confocal laser scanning and immunoelectron microscopy of MLL3AT protein
The complementary techniques of confocal laser scanning microscopy and immunoelectron microscopy were used to define the nuclear distribution of the MLL3AT protein more precisely. Confocal scanning microscopy of HtTA-1 cells con-
Figure 4
Association of the MLL and MLL3AT proteins with chromosomal scaffolds and nuclear matrix. To examine the association of the MLL3AT protein with chromosomal scaffolds, HtTA-1 cells expressing MLL3AT were doubled-labeled with (a) ␣-FLAG mAb and (b) ␣-topoisomerase II pAb. (c) Confocal imaging of these cells shows the distribution of ␣-FLAG mAb and ␣-topoisomerase II pAb in cells at various stages of the cell cycle (P, prophase; M, metaphase; T, telophase; I, interphase). MLL3AT and topoisomerase II colocalize in telophase and metaphase chromosomes (note the yellow color) with less association in prophase and interphase cells. Nuclear matrices prepared from HtTA-1 cells expressing MLL3AT were labeled with (d) ␣-FLAG mAb and (e) ␣-MLL mAb 2F7. Note that all antibodies label the chromosomal scaffolds in prophase (P) and telophase (T) cells and interphase (I) nuclear matrices. ditionally expressing MLL3AT clearly demonstrated punctate nucleoplasmic and intense nucleolar localization of MLL3AT stained with ␣-FLAG mAb (Figure 5a ). The three-dimensional image also showed the complete absence of label in some nucleoli (dark holes, indicated by large arrows), as well as the
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Figure 5
Confocal laser scanning microscopy of cells expressing MLL3AT. presence of label at the edge of the nuclear envelope (small arrows). A single optical section afforded a more detailed view from a cell that had been labeled with ␣-FLAG mAb (green) and stained for nucleic acids with propidium iodide (red) (Figure 5b ). The core of the nucleolus was stained with propidium iodide only, while the periphery was labeled with ␣-FLAG (red + green = yellow). These results extend the immunofluorescence studies by establishing an association of MLL3AT with the nuclear envelope and the periphery of nucleoli. Figure 6A illustrates the results of immunoelectron microscopic studies to localize MLL3AT protein in ultrathin sections of the nuclear compartment at high resolution. Sections of HtTA-1 cells expressing the FLAG-labeled protein were incubated with an ␣-FLAG mAb, followed by secondary antibodies coupled to colloidal gold particles. Clusters of gold particles, 0.1-0.2 m in diameter, were seen attached to the nuclear envelope, scattered throughout the nucleoplasm, and attached to the periphery of the nucleolus (arrowheads, Figure 6b ). Each cluster contains between 25 and 100 gold particles, indicating the presence of protein complexes containing multiple copies of MLL3AT molecules. In mitotic cells, metaphase chromosomes were heavily labeled with gold particles ( Figure 6C and inset) , confirming at high resolution an intimate association of MLL3AT with the condensed chromatin of chromosomes.
Figure 6
Immunoelectron microscopy of cells expressing MLL3AT. HeLa cells induced to express MLL3AT were labeled with the ␣-FLAG mAb, followed by a gold-conjugated secondary antibody. The clusters (0.1 to 0.2 m in diameter) of 25-100 gold particles observed by electron microscopy presumably represent the dots seen by fluorescence microscopy, and are located: (A) at the nuclear envelope (arrows); (B) at the periphery of the nucleolus and in the nucleoplasm (arrowheads); and (C) on the metaphase chromosomes (arrowhead, also shown in the inset). N, nucleus; Cy, cytoplasm; NE, nuclear envelope; NU, nucleolus; Ch, chromosome. Original magnifications: A, ×81 000; B, ×37 750; C, ×8500; C inset, ×46 000.
Conditional expression of MLL-AF4 protein in HeLa cells
We evaluated the subcellular distribution of conditionally expressed MLL-AF4 fusion oncoprotein in order to compare it with the MLL3AT and the endogenous MLL. A cDNA encoding the amino terminal FLAG epitope-tagged MLL-AF4 was generated and subcloned into pUHD-10S expression vector (Figure 1a) . Because of toxicity we could not develop HtTA-1 stable lines conditionally expressing MLL-AF4. 33 Thus, the pUHD/MLL-AF4 construct was transiently transfected into HtTA-1, and the MLL-AF4 protein was then expressed by tetracycline withdrawal. As shown in Figure 7 , immunofluorescence study with ␣-FLAG mAb (fluorescein) and anti-AF4 pAb C15 (Texas red) revealed a nuclear punctate distribution of the chimeric protein, with some spots associated with the nuclear envelope and others surrounding the nucleoli, as proved by phase contrast analysis. Taken together, these and previous results 33 point to an identical nuclear distribution pattern of native MLL, chimeric MLL-AF4 and MLL-AF9 proteins, and MLL3AT mutant, suggesting that the amino terminal portion of MLL containing three AT-hook motifs is responsible for targeting the fusion proteins to nuclear sites that appear to be those normally recognized by native MLL.
Discussion
The eukaryotic interphase nuclei contain a proteinaceous matrix that organizes them into structural and functional domains and that attaches at the interior of nuclear envelope, while the mitotic chromosomes contain a proteinaceous scaf- MLL-AF4 fusion oncoprotein associates with nucleoli and nucleoplasm. Cells transiently transfected with plasmid encoding FLAG-epitope tagged MLL-AF4 under control of a tet-suppressible promoter were grown for 36 h in the absence of tetracycline, and then colabeled with (a) ␣-FLAG mAb (green) and (b) ␣-AF4 pAb C15 (red). The HtTA-1 cell in panels a and b was also analyzed by phase contrast microscopy (c) to reveal the nucleoli (Nu). Note the ring-like nucleolar labeling with both ␣-FLAG and ␣-AF4 antibodies. As MLL and MLL3AT proteins, MLL-AF4 was localized in a nucleolar pattern and with a granular distribution throughout the nucleus.
fold around which the chromatin is organized into loop domains through scaffold attachment regions (SARs) of DNA. [43] [44] [45] A precursor-product relationship between the two scaffolds has been proposed, where the metaphase chromosome organization is in part maintained by the same nuclear matrix proteins, like topoisomerase II, which organize interphase chromatin. 46 Topoisomerase II is the major component of both interphase and metaphase scaffolds and it is thought to bind at SARs positioned at the base of the chromatin loops. [47] [48] [49] [50] Previously, endogenous MLL was shown to localize in a speckled pattern across the nuclei and at the nuclear envelope of a wide range of hematopoietic and nonhematopoietic cell lines, 41, [51] [52] [53] or bound to the periphery of condensing chromosomes of peripheral blood mononuclear cells. 54 Here, we show that the amino terminal 50 kDa fragment spanning 3-AT hook motifs colocalizes with topoisomerase II on mitotic chromosomes and targets MLL to interphase nuclear matrix and mitotic chromosomal scaffolds. In addition, we demonstrated clustered localization of MLL3AT throughout the nucleoplasm and to the nuclear envelope, suggesting that even MLL associates with SARs of the chromatin filament. These A/T-rich DNA elements of variable size, which mediate attachments with the interphase nuclear matrix and metaphase scaffolding, are critical for chromosome condensation 55 and for organizing the chromatin of mitotic chromosomes into loops that probably play important functional roles in gene expression (reviewed in Ref. 56) . Indeed, SARs are frequently observed in close association with enhancer elements, stimulate expression of heterologous reporter genes that are integrated into the genome, and may facilitate chromatin unfolding. AT-hook DNA-binding motifs, originally described in the HMG-I/Y proteins, are now identified in a wide range of known or predicted chromosomal/DNA-binding proteins. 57 AT-hook motifs bind the A/T-rich DNA of SARs via minor groove contacts, presumably by recognizing the bent secondary structure characteristic of these sequences. 29, 55 Since the amino terminal fragment of MLL contains three AT-hook motifs, which appear to bind to SARbut not non-SAR-containing DNA, 58 we propose that MLL binding to the SARs of metaphase chromosomes, mediated by the amino terminal AT-hook domains, affect chromatin structure and thereby exert epigenetic control over gene expression.
The nuclear punctate distribution of endogenous MLL and ectopically expressed MLL-AF4 or MLL-AF9 oncoproteins demonstrated in the present and the past study was previously Leukemia reported by Yano et al, 53 using anti-FLAG and anti-peptide Abs with COS, HeLa or SV80 cells, or cell lines expressing chimeric MLL proteins. Several polypeptides within the amino terminal region were found to direct nuclear localization of endogenous MLL and chimeric MLL proteins. Particularly, two polypeptides spanning short regions of homology to Trx, named SNL-1 and SNL-2, were found to confer speckled nuclear localization of MLL, leading the authors to conclude that the role of the amino terminal portion of MLL is to guide the endogenous protein and its various partners into the nucleus and to sites normally targeted by MLL. Joh et al 41, 52 likewise attributed the nuclear localization of MLL peptides to the amino terminal portion of the molecule, showing that a region containing AT-hook DNA-binding motifs was the common feature of deletion mutants found in cell nuclei. The MLL3AT mutant used in our study included both the AT-hook motifs and most of the SNL-1 domain extended between amino acids 322 and 480 of MLL, thus delimiting the amino terminal portion of MLL responsible for targeting of native MLL and chimeric MLL proteins to speckles associated with the nucleoplasm, the periphery of the nucleoli, and the nuclear envelope. In particular, the binding of MLL proteins to the periphery of the nucleolus remains to be understood. Nuclear matrix localization studies reveal association of MLL with a component within the nucleolar surface that is removed during the extraction procedure. Furthermore, inside the same cells not all the nucleoli seem to be stained by MLL3AT at the same time, thus suggesting a shuttling of the protein between the nuclear compartments. It is possible that the nucleolar binding reflects the affinity of the AT-hook DNA binding domains of MLL3AT to the nucleic acids, whether RNA or DNA, associated with periphery of the nucleolus, but further work is needed to address this issue.
Despite abundant evidence linking native MLL and its chimeric forms to sites of action in the nucleus, there are few clues to the molecular events that might induce leukemic transformation. It is still unclear whether the MLL chimeric or self-fused proteins behave as a true oncogene product 28 (conferring a gain of activity) or as a dominant negative inhibitor 11, 20 of normal MLL function. In favor of the second possibility is the observation that MLL fusion proteins lack the carboxyl terminal MLL sequences that constitute the chromatinspecific PHD fingers 17 and SET domain, 21 whose sequences share the highest homology with trx Drosophila protein. As for trx and Pc-G proteins, colocalization on a subset of bands in Drosophila polytene chromosomes, 59 the association of MLL to mitotic chromosomes or at the edge of the nuclear envelope may reflect a similar organization into multiprotein complexes that localizes at genomic sites containing subordinate target genes (eg HOX genes). 53 Our findings clearly link the localization of MLL to the SAR regions of interphase and metaphase chromosomes. Therefore, SARs may be one of the AT-rich DNA regulatory elements to which amino terminal AT-hook domains anchor the MLL protein and by which MLL maintains cell type-specific patterns of target genes expression through epigenetic mechanisms that establish and sustain a receptive chromatin configuration. This observation, together with those showing the ability of MLL-AF9 amino terminal AThook domains to block cell cycle progression and promote partial myelomonocytic differentiation by itself, 33 suggests that disruption of critical patterns of gene expression (eg CD11b, p21
Cip1 , p27 Kip1 ) by competition for specific DNA regulatory elements (eg SARs) normally recognized by native MLL, lies at the core of leukemogenesis induced by MLL chimeric proteins.
Leukemia
Interestingly, translocations involving both HMGI-C and HMGI(Y) members of the HMGI family of architectural proteins have been identified in a variety of benign mesenchymal tumors (reviewed in Ref. 60 ). In particular, cytogenetic analysis indicated the possibility of a great number of alternative sequences positioned downstream of the three AT-hook motifs of HMGI-C in various rearrangements found in lipomas and other benign solid tumor types. 61, 62 Therefore, the real structural alteration responsible for cell transformation might be the separation by different partner genes of the three AT-hook motifs from the carboxyl terminal acidic tail of HMGI-C. 63 Recent studies showed that chimeric mice carrying fusion of truncated Mll with bacterial ␤-galactosidase (Mll-lacZ) developed acute leukemia, although with a longer latency period compared to those carrying Mll-AF9 knock-in gene. Thus, Mll-lacZ fusion gene was sufficient to cause leukemia in mice. Conversely, Mll AT-hooks-lacZ fusion failed to develop acute leukemias in an experimental period of 12 months. 64, 65 In our experiments, complete myelomonocytic differentiation and cell death obtained with MLL-AF9 forced expression was not seen with expression of the amino terminal AT-hook motifs alone, but required downstream MLL sequences, including the MT domain. The MT domain, like the AT-hook motifs, has been previously defined as necessary for leukemic transformation. 28 For instance, it may function like the homologous repressor domain of the DNA methyltransferase I protein by recruiting histone deacetylase activity, 66 therefore complementing the SAR-mediated transcriptional regulatory effects played by the amino terminal AT-hooks alone. As postulated by Dobson et al, 65 if the truncated MLL functions as a dominant negative molecule, operating in the absence of carboxyl terminal PHD fingers and SET domain, then the partner genes might be required to confer stabilization to the truncated MLL protein or might confer protein-protein interacting domains, as for synthetic fusion with ␤-galactosidase. Otherwise, the partner gene might have a direct role in the transforming ability of chimeric proteins. 28 Thus, the MLL amino terminus may influence the ability of normal MLL to modulate chromatin-mediated gene expression, contributing in part to the oncogenic activities of the fusion oncoproteins.
